title: CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer.
abstract: Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.
authors.affiliation: Department of Neurology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
authors.forename: S
authors.initials: S
authors.lastname: Sengupta
authors.affiliation: Department of Neuroradiology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
authors.forename: R
authors.initials: R
authors.lastname: Rojas
authors.affiliation: Department of Radiation Oncology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
authors.forename: A
authors.initials: A
authors.lastname: Mahadevan
authors.affiliation: Department of Neurosurgery , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
authors.forename: E
authors.initials: E
authors.lastname: Kasper
authors.affiliation: Department of Neurology, Tuft Medical School, Tufts Medical Center, Boston, MA.
authors.forename: S
authors.initials: S
authors.lastname: Jeyapalan